Does the media refer more to IMNM or ARWR?

In the previous week, Immunome had 1 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 9 mentions for Immunome and 8 mentions for Arrowhead Pharmaceuticals. Immunome's average media sentiment score of 0.61 beat Arrowhead Pharmaceuticals' score of 0.26 indicating that Immunome is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, IBRX or IMNM?

Immunome has lower revenue, but higher earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $113.29M 92.71 -$351.40M -$0.97 N/A Immunome $6.94M 316.03 -$212.39M -$2.53 N/A

Is IBRX or IMNM more profitable?

Immunome has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets ImmunityBio -598.55% N/A -51.65% Immunome N/A -50.56% -46.93%

Does the media prefer IBRX or IMNM?

In the previous week, ImmunityBio had 3 more articles in the media than Immunome. MarketBeat recorded 12 mentions for ImmunityBio and 9 mentions for Immunome. Immunome's average media sentiment score of 0.61 beat ImmunityBio's score of 0.55 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunome 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IMNM or KYMR?

In the previous week, Immunome had 6 more articles in the media than Kymera Therapeutics. MarketBeat recorded 9 mentions for Immunome and 3 mentions for Kymera Therapeutics. Immunome's average media sentiment score of 0.61 beat Kymera Therapeutics' score of 0.42 indicating that Immunome is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PTGX or IMNM?

In the previous week, Immunome had 3 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 9 mentions for Immunome and 6 mentions for Protagonist Therapeutics. Immunome's average media sentiment score of 0.61 beat Protagonist Therapeutics' score of 0.53 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunome 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, IMNM or PCVX?

Immunome has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunome $6.94M 316.03 -$212.39M -$2.53 N/A Vaxcyte N/A N/A -$766.63M -$7.63 N/A

Is IMNM or PCVX more profitable?

Vaxcyte's return on equity of -37.56% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Immunome N/A -50.56% -46.93% Vaxcyte N/A -37.56% -33.62%

Does the media favor IMNM or PCVX?

In the previous week, Vaxcyte had 39 more articles in the media than Immunome. MarketBeat recorded 48 mentions for Vaxcyte and 9 mentions for Immunome. Immunome's average media sentiment score of 0.61 beat Vaxcyte's score of 0.52 indicating that Immunome is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 16 Very Positive mention(s) 10 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Immunome (IMNM) Competitors

$19.32 +0.02 (+0.08%)

As of 11:18 AM Eastern

Compare

IMNM vs. ARWR, IBRX, KYMR, PTGX, and PCVX

Should you buy Immunome stock or one of its competitors? Immunome's main competitors and comparable companies include Arrowhead Pharmaceuticals (ARWR), ImmunityBio (IBRX), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), and Vaxcyte (PCVX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immunome compare to Arrowhead Pharmaceuticals?

Immunome (NASDAQ:IMNM) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

In the previous week, Immunome had 1 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 9 mentions for Immunome and 8 mentions for Arrowhead Pharmaceuticals. Immunome's average media sentiment score of 0.61 beat Arrowhead Pharmaceuticals' score of 0.26 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunome has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Immunome's return on equity of -50.56% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-50.56%	-46.93%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

Arrowhead Pharmaceuticals has higher revenue and earnings than Immunome. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	316.03	-$212.39M	-$2.53	N/A
Arrowhead Pharmaceuticals	$829.45M	10.32	-$1.63M	-$2.25	N/A

Immunome currently has a consensus target price of $34.25, suggesting a potential upside of 77.37%. Arrowhead Pharmaceuticals has a consensus target price of $98.31, suggesting a potential upside of 61.85%. Given Immunome's stronger consensus rating and higher probable upside, equities research analysts clearly believe Immunome is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

44.6% of Immunome shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 7.2% of Immunome shares are held by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Immunome has a beta of 2.55, indicating that its stock price is 155% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market.

Summary

Immunome beats Arrowhead Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Immunome compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Immunome (NASDAQ:IMNM) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Immunome has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
Immunome	N/A	-50.56%	-46.93%

ImmunityBio has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market. Comparatively, Immunome has a beta of 2.55, suggesting that its share price is 155% more volatile than the broader market.

ImmunityBio currently has a consensus price target of $14.20, suggesting a potential upside of 43.29%. Immunome has a consensus price target of $34.25, suggesting a potential upside of 77.37%. Given Immunome's higher possible upside, analysts clearly believe Immunome is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Immunome	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Immunome has lower revenue, but higher earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	92.71	-$351.40M	-$0.97	N/A
Immunome	$6.94M	316.03	-$212.39M	-$2.53	N/A

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by insiders. Comparatively, 7.2% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, ImmunityBio had 3 more articles in the media than Immunome. MarketBeat recorded 12 mentions for ImmunityBio and 9 mentions for Immunome. Immunome's average media sentiment score of 0.61 beat ImmunityBio's score of 0.55 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunome	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Immunome beats ImmunityBio on 10 of the 17 factors compared between the two stocks.

How does Immunome compare to Kymera Therapeutics?

Immunome (NASDAQ:IMNM) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Immunome has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	316.03	-$212.39M	-$2.53	N/A
Kymera Therapeutics	$39.21M	231.79	-$311.35M	-$3.24	N/A

44.6% of Immunome shares are owned by institutional investors. 7.2% of Immunome shares are owned by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Immunome had 6 more articles in the media than Kymera Therapeutics. MarketBeat recorded 9 mentions for Immunome and 3 mentions for Kymera Therapeutics. Immunome's average media sentiment score of 0.61 beat Kymera Therapeutics' score of 0.42 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunome has a beta of 2.55, suggesting that its share price is 155% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market.

Immunome has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-50.56%	-46.93%
Kymera Therapeutics	-285.33%	-21.22%	-19.21%

Immunome currently has a consensus target price of $34.25, suggesting a potential upside of 77.37%. Kymera Therapeutics has a consensus target price of $134.68, suggesting a potential upside of 23.22%. Given Immunome's higher possible upside, analysts clearly believe Immunome is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Immunome beats Kymera Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Immunome compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Immunome (NASDAQ:IMNM) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

Protagonist Therapeutics currently has a consensus price target of $147.13, suggesting a potential upside of 5.16%. Immunome has a consensus price target of $34.25, suggesting a potential upside of 77.37%. Given Immunome's higher probable upside, analysts clearly believe Immunome is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89
Immunome	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Protagonist Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market. Comparatively, Immunome has a beta of 2.55, suggesting that its stock price is 155% more volatile than the broader market.

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 7.2% of Immunome shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Immunome had 3 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 9 mentions for Immunome and 6 mentions for Protagonist Therapeutics. Immunome's average media sentiment score of 0.61 beat Protagonist Therapeutics' score of 0.53 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunome	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protagonist Therapeutics has a net margin of 29.40% compared to Immunome's net margin of 0.00%. Protagonist Therapeutics' return on equity of 12.03% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Immunome	N/A	-50.56%	-46.93%

Protagonist Therapeutics has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$281.99M	32.10	-$130.15M	$1.03	135.83
Immunome	$6.94M	316.03	-$212.39M	-$2.53	N/A

Summary

Protagonist Therapeutics beats Immunome on 10 of the 16 factors compared between the two stocks.

How does Immunome compare to Vaxcyte?

Immunome (NASDAQ:IMNM) and Vaxcyte (NASDAQ:PCVX) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Immunome has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	316.03	-$212.39M	-$2.53	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

Immunome currently has a consensus price target of $34.25, suggesting a potential upside of 77.37%. Vaxcyte has a consensus price target of $108.60, suggesting a potential upside of 67.05%. Given Immunome's stronger consensus rating and higher possible upside, analysts clearly believe Immunome is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Vaxcyte's return on equity of -37.56% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-50.56%	-46.93%
Vaxcyte	N/A	-37.56%	-33.62%

Immunome has a beta of 2.55, indicating that its share price is 155% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

44.6% of Immunome shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 7.2% of Immunome shares are owned by insiders. Comparatively, 3.3% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Vaxcyte had 39 more articles in the media than Immunome. MarketBeat recorded 48 mentions for Vaxcyte and 9 mentions for Immunome. Immunome's average media sentiment score of 0.61 beat Vaxcyte's score of 0.52 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	16 Very Positive mention(s)	10 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Immunome beats Vaxcyte on 10 of the 14 factors compared between the two stocks.

Get Immunome News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMNM vs. The Competition

Export

Metric	Immunome	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.19B	$3.86B	$7.19B	$13.26B
Dividend Yield	N/A	3.65%	2.53%	16.36%
P/E Ratio	-7.62	13.28	274.59	26.08
Price / Sales	N/A	1,188.35	584.73	80.90
Price / Cash	N/A	117.60	76.82	53.72
Price / Book	3.36	16.39	10.90	6.29
Net Income	-$212.39M	-$22.69M	$3.50B	$382.01M
7 Day Performance	-7.54%	-1.98%	-1.28%	-1.32%
1 Month Performance	-26.01%	-10.27%	-5.78%	-4.30%
1 Year Performance	35.23%	9.20%	3.80%	-0.49%

Immunome Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMNM Immunome	2.8408 of 5 stars	$19.33 +0.1%	$34.25 +77.2%	+37.8%	$2.19B	N/A	N/A	177
ARWR Arrowhead Pharmaceuticals	2.728 of 5 stars	$65.41 -0.1%	$98.31 +50.3%	+64.4%	$9.22B	$829.45M	N/A	711
IBRX ImmunityBio	3.0009 of 5 stars	$8.71 +2.3%	$14.20 +63.0%	+291.7%	$9.21B	$113.29M	N/A	691	News Coverage Analyst Forecast Insider Trade
KYMR Kymera Therapeutics	2.1566 of 5 stars	$109.76 -2.0%	$133.21 +21.4%	+94.2%	$9.12B	$39.21M	N/A	273	Analyst Forecast
PTGX Protagonist Therapeutics	1.5833 of 5 stars	$139.83 -1.8%	$147.13 +5.2%	+114.3%	$9.06B	$46.02M	135.99	141

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMNM) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunome (IMNM) Competitors

IMNM vs. ARWR, IBRX, KYMR, PTGX, and PCVX

How does Immunome compare to Arrowhead Pharmaceuticals?

Summary

How does Immunome compare to ImmunityBio?

Summary

How does Immunome compare to Kymera Therapeutics?

Summary

How does Immunome compare to Protagonist Therapeutics?

Summary

How does Immunome compare to Vaxcyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM vs. The Competition

Immunome Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunome (IMNM) Competitors

IMNM vs. ARWR, IBRX, KYMR, PTGX, and PCVX

How does Immunome compare to Arrowhead Pharmaceuticals?

Does the media refer more to IMNM or ARWR?

Is IMNM or ARWR more profitable?

Which has stronger valuation & earnings, IMNM or ARWR?

Do analysts rate IMNM or ARWR?

Do institutionals and insiders have more ownership in IMNM or ARWR?

Which has more volatility and risk, IMNM or ARWR?

Summary

How does Immunome compare to ImmunityBio?

Is IBRX or IMNM more profitable?

Which has more risk & volatility, IBRX or IMNM?

Do analysts rate IBRX or IMNM?

Which has preferable valuation and earnings, IBRX or IMNM?

Do insiders and institutionals hold more shares of IBRX or IMNM?

Does the media prefer IBRX or IMNM?

Summary

How does Immunome compare to Kymera Therapeutics?

Which has stronger valuation and earnings, IMNM or KYMR?

Do insiders & institutionals have more ownership in IMNM or KYMR?

Does the media refer more to IMNM or KYMR?

Which has more risk and volatility, IMNM or KYMR?

Is IMNM or KYMR more profitable?

Do analysts prefer IMNM or KYMR?

Summary

How does Immunome compare to Protagonist Therapeutics?

Do analysts prefer PTGX or IMNM?

Which has more volatility & risk, PTGX or IMNM?

Do institutionals & insiders have more ownership in PTGX or IMNM?

Does the media refer more to PTGX or IMNM?

Is PTGX or IMNM more profitable?

Which has higher valuation & earnings, PTGX or IMNM?

Summary

How does Immunome compare to Vaxcyte?

Which has better valuation and earnings, IMNM or PCVX?

Do analysts rate IMNM or PCVX?

Is IMNM or PCVX more profitable?

Which has more risk and volatility, IMNM or PCVX?

Do insiders & institutionals hold more shares of IMNM or PCVX?

Does the media favor IMNM or PCVX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM vs. The Competition

Immunome Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools